Patents by Inventor Elvira Favoino
Elvira Favoino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11078260Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: GrantFiled: January 12, 2018Date of Patent: August 3, 2021Assignee: University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20180230205Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: January 12, 2018Publication date: August 16, 2018Applicant: University of Pittsburgh - Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Patent number: 9902766Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: GrantFiled: April 6, 2016Date of Patent: February 27, 2018Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20160207990Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: April 6, 2016Publication date: July 21, 2016Applicant: University of Pittsburgh - Of The Commonwealth Sys tem of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Patent number: 9340608Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: GrantFiled: June 27, 2013Date of Patent: May 17, 2016Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Patent number: 9296811Abstract: Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds high molecular weight melanoma associated antigen (HMW-MAA), also known as CSPG4; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.Type: GrantFiled: December 1, 2011Date of Patent: March 29, 2016Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Elvira Favoino, Ling Yu, Yangyang Wang
-
Publication number: 20140234324Abstract: Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.Type: ApplicationFiled: May 2, 2014Publication date: August 21, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Elvira Favoino, Ling Yu, Yangyang Wang
-
Patent number: 8771687Abstract: Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.Type: GrantFiled: December 1, 2011Date of Patent: July 8, 2014Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Elvira Favoino, Ling Yu, Yangyang Wang
-
Publication number: 20140010811Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: June 27, 2013Publication date: January 9, 2014Applicant: University of Pittsburgh - Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20130259873Abstract: Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds high molecular weight melanoma associated antigen (HMW-MAA), also known as CSPG4; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.Type: ApplicationFiled: December 1, 2011Publication date: October 3, 2013Inventors: Soldano Ferrone, Xinhui Wang, Elvira Favoino, Ling Yu, Yangyang Wang
-
Patent number: 8497354Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: GrantFiled: June 15, 2011Date of Patent: July 30, 2013Assignee: University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20120148598Abstract: Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.Type: ApplicationFiled: December 1, 2011Publication date: June 14, 2012Inventors: Soldano Ferrone, Xinhui Wang, Elvira Favoino, Ling Yu, Yangyang Wang
-
Publication number: 20120009194Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: June 15, 2011Publication date: January 12, 2012Inventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood